ArticleScientific reports2025
S100 A16 promotes the progression of osteosarcoma by activating the PI3 K/AKT signaling pathway through ANXA2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- S100 Calcium-Binding Protein 16 (S100A16) Promotes Hepatic Stellate Cell Activation Via Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)-mediated Glycolysis to Facilitate Liver Fibrosis.Cell biochemistry and function · 2026Article
- Molecular mechanisms and genetic predisposition to osteoarthritis and osteosarcoma through Mendelian inheritance patterns.Discover oncology · 2025Article
- Relationship of S100 Proteins with Neuroinflammation.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma is a common primary malignant bone tumor. S100A16 gene was reported to highly expressed in several tumor tissues while the relationship between S100A16 and osteosarcoma remains less well-understood. This study aimed to investigate the expression characteristics of S100A16 in osteosarcoma and the mechanism by which it promotes osteosarcoma progression. Firstly, by analyzing databases and assessing mRNA and protein level, we found that the expression of S100A16 was significantly promoted in osteosarcoma, as compared with normal tissue. Then transfection techniques were employed to upregulate and downregulate S100A16 in osteosarcoma cells, the results demonstrated that S100A16 can increase osteosarcoma cell viability, migration and invasion capacities, while decline osteosarcoma cell apoptosis. GSEA (gene set enrichment analysis) revealed that increased expression of S100A16 was enriched in the PI3K/AKT pathway. Cellular experiments showed that the S100A16 promoted osteosarcoma progression by activating the PI3K/AKT signaling pathway, and upregulated expression of ANXA2, a crucial protein in occurrence and development of tumors. We also found that overexpression of ANXA2 can restore the decreased levels of p-PI3K and p-AKT induced by S100A16 inhibition, which indicated that S100A16 stimulates PI3K/AKT pathway activation via ANXA2. To sum up, S100A16 can promotes osteosarcoma progression by activating the PI3K/AKT signaling pathway through ANXA2, suggesting that the S100A16/ANXA2 axis may represent a novel therapeutic target for osteosarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.